Insider

Takeda reports revenue growth and revises its fiscal-year forecast

Takeda reported first-half fiscal 2026 results on October 29. Revenue was 2,407.0 billion yen, up 8.4% at actual exchange rates but down 1.0% at constant rates. The company also revised its forecast for the fiscal year ending March 2027.

Verified against 4 archived primary sources · SHA-256 recorded Inspect sources & citations ↓
a long hallway with pictures on the walls
Photo by zhang shuaizhang on Unsplash
2,407.0 billion yen
First-half revenue
8.4%
Revenue growth, actual rates

Key points

  • The company said revenue growth was mainly due to the weaker Japanese yen.
  • In the United States, sales in gastroenterology (GI) rose 10.3% at actual exchange rates, to 351.8 billion yen.
  • Two executives, the president of the Global Oncology business unit and the president of the International business unit, filed notices of proposed sales of American Depositary Shares (ADSs): 46,609 and 55,617 units, respectively.

First-half results

The company said revenue growth was mainly due to the weaker Japanese yen. Excluding currency effects, core revenue declined slightly: growth in new launches did not offset declines in products that lost exclusivity and in mature products.

Amortization and impairment losses on intangible assets fell to 218.5 billion yen, down 35.1% at actual exchange rates. Other operating expenses rose instead, because restructuring under the transformation program added 52.4 billion yen.

Sales growth at actual exchange rates

First-half revenue
8.4%
TRINTELLIX
25.2%
GI in the U.S.
10.3%
Data from the original sources listed alongside.

Other news of the period

In the United States, sales in gastroenterology (GI) rose 10.3% at actual exchange rates, to 351.8 billion yen. The company attributes this to exchange rates and growth in the subcutaneous form of the drug.

TRINTELLIX sales rose 25.2% at actual exchange rates, to 71.3 billion yen, mainly due to pricing in the U.S.

On October 29 the company filed its semi-annual report in Japan. It reports no new risk factors compared with its annual report and no significant changes in risks.

Executives' proposed share sales

Two executives, the president of the Global Oncology business unit and the president of the International business unit, filed notices of proposed sales of American Depositary Shares (ADSs): 46,609 and 55,617 units, respectively. The approximate sale date is November 1, 2026. Such a notice does not mean the sale has already taken place.

The company says these shares were acquired on July 30, 2024, through restricted stock units that have already vested.

What the data does not show

No reason for the forecast revision is given in these materials. The reports also do not show whether the proposed sale took place.

What to watch

The next full-year report will show whether results match the revised forecast at constant exchange rates, where a decline in key measures is expected.

Also watch restructuring costs: the next report will show whether they keep rising under the transformation program.

Original sources

  1. 6-K filing, October 29, 2026October 29, 2026SHA-256 of our archived copy 25f3b360f561…
  2. 6-K filing, October 29, 2026October 29, 2026SHA-256 of our archived copy 811e6771f70a…
  3. 144 filing, October 30, 2026October 30, 2026SHA-256 of our archived copy 9ef7900e879a…
  4. 144 filing, October 30, 2026October 30, 2026SHA-256 of our archived copy c48d4e5ba806…
Cite this article

The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.

Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards